How much does a box of Platinib capsules cost in 2024?

Pralsetinib (Pralsetinib) belongs to a class of targeted drugs for the treatment of RET mutated tumors. It can block the growth and proliferation signaling pathways of tumor cells by inhibiting the activity of RET kinase. It has demonstrated significant efficacy in the treatment of RET-driven cancers such as non-small cell lung cancer (NSCLC) and thyroid cancer. The launch of platinib provides a new treatment option for these patients, especially those who have poor response to traditional chemotherapy and radiotherapy.

However, the high price of platinib has become a barrier to accessing treatment for many patients. In China, the specification of the original drug Platinib is 100mg*120 pills per box, and the price may be as high as 60,000 yuan. Since it is not covered by medical insurance, the patient needs to bear the full cost out of pocket. For most patients, this is undoubtedly a heavy financial burden.

In addition, the prices of overseas versions of platinib also vary greatly. The specifications of the European and American versions are100mg*60 capsules per box, and the price may fluctuate between RMB 40,000 and RMB 150,000, which is significantly affected by the exchange rate. This price instability further makes it more difficult for patients to obtain medications.

It is worth noting that there are currently generic drugs of Platinib on the market. The ingredients of this drug are basically the same as those of the original drugs sold at home and abroad, but the price is relatively low. For example, the specification of Seputinib produced by a Lao pharmaceutical factory is 100mg*120 pills per box, and the price may be around 4,000 yuan. The advent of generic drugs may provide patients with a more economical option.

In general, platinib, as an innovative anti-cancer drug, brings new hope to patients with RET mutation tumors. However, its high price and limited accessibility remain important factors limiting patients' access to treatment. In the future, we expect more policy support and market competition to lower the price of this drug so that it can benefit more patients.